Alkermes plc (ALKS)Healthcare | Drug Manufacturers - Specialty & Generic | Dublin, Ireland | NasdaqGS
51.87 USD
-0.07
(-0.135%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 51.81 -0.06 (-0.060%) ⇩ (July 13, 2026, 7:25 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:20 a.m. EDT
The immediate outlook is mixed, driven by a disconnect between recent price strength and underlying valuation concerns. The stock has rallied significantly off its lows, trading well above its 200-day average, yet the fundamental picture remains precarious with negative operating margins and a trailing P/E of nearly 58. While the recent 28% revenue growth is impressive, the market appears skeptical of its sustainability given the persistent losses. The options data confirms this hesitation; traders are buying protection at lower levels while capping their upside bets, creating a ceiling for further immediate gains. The statistical forecast offers only a weak lean upward, reinforcing the view that the recent rally may be running ahead of the earnings reality. Until operating profitability turns consistently positive, the high valuation leaves little room for error. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.136362 |
| AutoETS | 0.136554 |
| AutoARIMA | 0.136556 |
| MSTL | 0.149155 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 64.93 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.109 |
| Excess Kurtosis | -1.42 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 90.302 |
| Revenue per Share | 9.446 |
| Market Cap | 8,645,474,304 |
| Trailing P/E | 57.63 |
| Forward P/E | 31.67 |
| Beta | 0.29 |
| Profit Margins | 9.77% |
| Website | https://www.alkermes.com |
As of July 11, 2026, 6:20 a.m. EDT: Speculators are positioning for a volatile range-bound outcome rather than a decisive breakout. Call volume is concentrated near the money (45-55 strikes) with significant open interest walls acting as resistance, while put volume is heavily skewed toward lower strikes (30-45), indicating a floor is expected around the 30-40 zone. The implied volatility surface shows elevated premiums for deep out-of-the-money puts relative to calls, suggesting the market prices in a high probability of a drop to the 30s but limited upside beyond current levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.7494106 |
| Address1 | Connaught House |
| Address2 | 1 Burlington Road Dublin 4 |
| All Time High | 98.5 |
| All Time Low | 0.9375 |
| Ask | 58.7 |
| Ask Size | 1 |
| Audit Risk | 3 |
| Average Analyst Rating | 1.7 - Buy |
| Average Daily Volume10 Day | 2,524,910 |
| Average Daily Volume3 Month | 2,235,719 |
| Average Volume | 2,235,719 |
| Average Volume10Days | 2,524,910 |
| Beta | 0.294 |
| Bid | 44.45 |
| Bid Size | 1 |
| Board Risk | 5 |
| Book Value | 10.522 |
| City | Dublin |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 2 |
| Country | Ireland |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 51.87 |
| Current Ratio | 2.266 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 52.0 |
| Day Low | 50.54 |
| Debt To Equity | 90.302 |
| Display Name | Alkermes |
| Earnings Call Timestamp End | 1,777,982,400 |
| Earnings Call Timestamp Start | 1,777,982,400 |
| Earnings Timestamp | 1,777,984,200 |
| Earnings Timestamp End | 1,785,241,800 |
| Earnings Timestamp Start | 1,785,241,800 |
| Ebitda | 278,583,008 |
| Ebitda Margins | 0.17832 |
| Enterprise To Ebitda | 34.874 |
| Enterprise To Revenue | 6.219 |
| Enterprise Value | 9,715,271,680 |
| Eps Current Year | 1.23376 |
| Eps Forward | 1.63799 |
| Eps Trailing Twelve Months | 0.9 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 43.0448 |
| Fifty Day Average Change | 8.825199 |
| Fifty Day Average Change Percent | 0.20502359 |
| Fifty Two Week Change Percent | 74.94106 |
| Fifty Two Week High | 55.67 |
| Fifty Two Week High Change | -3.7999992 |
| Fifty Two Week High Change Percent | -0.06825937 |
| Fifty Two Week Low | 25.17 |
| Fifty Two Week Low Change | 26.699999 |
| Fifty Two Week Low Change Percent | 1.0607866 |
| Fifty Two Week Range | 25.17 - 55.67 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 679,671,000,000 |
| Float Shares | 154,083,450 |
| Forward Eps | 1.63799 |
| Forward P E | 31.666859 |
| Free Cashflow | 140,551,632 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 2,050 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.87447 |
| Gross Profits | 1,366,188,032 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01426 |
| Held Percent Institutions | 1.10656 |
| Implied Shares Outstanding | 166,675,807 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ir Website | http://investor.alkermes.com/phoenix.zhtml?c=92211&p=irol-irhome |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 958,348,800 |
| Last Split Factor | 2:1 |
| Long Business Summary | Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. |
| Long Name | Alkermes plc |
| Market | us_market |
| Market Cap | 8,645,474,304 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_24572 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | 152,720,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,658,808,173 |
| Number Of Analyst Opinions | 17 |
| Open | 51.07 |
| Operating Cashflow | 256,200,000 |
| Operating Margins | -0.0019200001 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Peg Ratio | 1.96 |
| Phone | 353 1 772 8000 |
| Post Market Change | -0.05999756 |
| Post Market Change Percent | -0.115669094 |
| Post Market Price | 51.81 |
| Post Market Time | 1,783,985,113 |
| Previous Close | 51.94 |
| Price Eps Current Year | 42.042213 |
| Price Hint | 2 |
| Price To Book | 4.929671 |
| Price To Sales Trailing12 Months | 5.5338116 |
| Profit Margins | 0.09774999 |
| Quick Ratio | 1.534 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 1.66667 |
| Region | US |
| Regular Market Change | -0.0699997 |
| Regular Market Change Percent | -0.13477 |
| Regular Market Day High | 52.0 |
| Regular Market Day Low | 50.54 |
| Regular Market Day Range | 50.54 - 52.0 |
| Regular Market Open | 51.07 |
| Regular Market Previous Close | 51.94 |
| Regular Market Price | 51.87 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,561,418 |
| Return On Assets | 0.047199998 |
| Return On Equity | 0.0936 |
| Revenue Growth | 0.282 |
| Revenue Per Share | 9.446 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 166,675,807 |
| Shares Percent Shares Out | 0.10479999 |
| Shares Short | 17,464,944 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 17,355,226 |
| Short Name | Alkermes plc |
| Short Percent Of Float | 0.1456 |
| Short Ratio | 6.33 |
| Source Interval | 15 |
| Symbol | ALKS |
| Target High Price | 65.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 51.58824 |
| Target Median Price | 48.0 |
| Total Cash | 511,862,016 |
| Total Cash Per Share | 3.071 |
| Total Debt | 1,581,660,032 |
| Total Revenue | 1,562,300,032 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.9 |
| Trailing P E | 57.633335 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 33.8847 |
| Two Hundred Day Average Change | 17.985298 |
| Two Hundred Day Average Change Percent | 0.5307793 |
| Type Disp | Equity |
| Volume | 1,561,418 |
| Website | https://www.alkermes.com |
| Zip | D04 C5Y6 |